Table 1 Indication and therapeutic intervention.

Indication	Therapeutic intervention	Pre‐MRCP (n = )	Post‐MRCP (n = )	OR (95% CI)
Pain, biliary dilatation, abnormal LFTs±CBD stone on USS	Yes	31	40	2.92 (1.43–5.97)
Pain, biliary dilatation, abnormal LFTs±CBD stone on USS	No	43	19	2.92 (1.43–5.97)
Jaundice with biliary dilatation	Yes	70	44	0.53 (0.13–1.98)
Jaundice with biliary dilatation	No	4	5	0.53 (0.13–1.98)
Stent change	Yes	27	23	N/A
Stent change	No	0	0	N/A
Cholangitis	Yes	20	15	0.25 (0.02–2.65)
Cholangitis	No	1	3	0.25 (0.02–2.65)
Pain, jaundice, and CBD stone	Yes	12	18	3.00 (0.24–36.9)
Pain, jaundice, and CBD stone	No	2	1	3.00 (0.24–36.9)
Jaundice with epigastric mass	Yes	12	1	0.93 (0.82–1.07)
Jaundice with epigastric mass	No	13	2	0.93 (0.82–1.07)
Gall stone pancreatitis	Yes	8	9	0.84 (0.14–4.97)
Gall stone pancreatitis	No	3	4	0.84 (0.14–4.97)
Recurrent pancreatitis	Yes	3	3	5.50 ( 0.61–49.5)
Recurrent pancreatitis	No	11	2	5.50 ( 0.61–49.5)
Post cholecystectomy, recurrent pain, and deranged LFTs	Yes	6	5	1.67 (0.21–13.2)
Post cholecystectomy, recurrent pain, and deranged LFTs	No	4	2	1.67 (0.21–13.2)
Post cholecystectomy bile leak	Yes	0	2	N/A
Post cholecystectomy bile leak	No	0	1	N/A
Asymptomatic with deranged LFTs	Yes	0	0	N/A
Asymptomatic with deranged LFTs	No	0	2	N/A

MRCP, magnetic resonance cholangiopancreatography; CBD, common bile duct; LTFS, liver function tests; USS, ultrasound; N/A not applicable; OR (95% CI), odds ratio (95% confidence interval).